Darren K. Cheng

Darren K. Cheng

Auto-generated profile, based on publicly available information

Darren K. Cheng

Bridgepoint Collaboratory for Research and Innovation, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2019 in Topics in Stroke Rehabilitation
Verified
Journal Article
Closed access
DCDarren K. Cheng
Darren K. Cheng
MNMichelle Nelson
Michelle Nelson
DBDina Brooks
Dina Brooks
NSNancy M. Salbach
Nancy M. Salbach
Background: Stroke-specific protocols for the 10-meter and 6-minute walk tests that include instructions for people with aphasia, accessible walkway lengths, and allow provision of assistance to walk are needed to facilitate uptake in hospital settings. Objectives: To estimate the test-retest reliability, measurement error, and construct validity of stroke-specific protocols for the 10-meter walk test (10mWT), and 6-minute walk test conducted using a 15-meter walkway (6MWT15m) and 30-meter walkway (6MWT30m), in people post-stroke. Methods: A quantitative, cross-sectional study involving ambulatory people post-stroke was conducted. Results: Data were collected from 21 and 20 participants at baseline and retest, respectively, 1–3 days apart. Mean age was 61 years, median time post-stroke was 134 days, and 90% had experienced an ischemic stroke. Performance on the 10mWT, 6MWT15m, and 6MWT30m across sessions yielded intraclass correlation coefficient (ICC2, 1) estimates of test-retest reliability of 0.83, 0.97, 0.95, respectively, and minimal detectable change values at the 95% confidence level of 0.40m/s, 44.0m, and 67.5m, respectively. Pearson correlation coefficients were 0.80–0.95 (p < .001) between results on all three walk tests and 0.27–0.48 (p < .25) between walk test results and strength subscale scores on the Stroke Impact Scale. Conclusions: Findings showed excellent test-retest reliability; measurement error values similar to current literature; and support for construct validity of the 10mWT, 6MWT15m, and 6MWT30m. Due to the shorter walkway, the 6MWT15m may be more feasible to implement than the 6MWT30m in hospital settings. A larger sample with more severe deficits is required to improve generalizability.

9 August 2021 in Pain Medicine
Verified
Journal Article
Open access
PDF file
DCDarren K Cheng
Darren K Cheng
KLKa Sing Paris Lai
Ka Sing Paris Lai
OPOscar Javier Pico-Espinosa
Oscar Javier Pico-Espinosa
DRDanielle B Rice
Danielle B Rice
CCChadwick Chung
Chadwick Chung
ASAbhimanyu Sud
Abhimanyu Sud
Objective: This review investigated the effectiveness of clinical interventions on depressive symptoms in people with all types of chronic pain. Methods: We searched seven electronic databases and reference lists on September 15, 2020, and included English-language, systematic reviews and meta-analyses of trials that examined the effects of clinical interventions on depressive outcomes in chronic pain. Two independent reviewers screened, extracted, and assessed the risk of bias. PROSPERO registration: CRD42019131871. Results: Eighty-three reviews were selected and included 182 meta-analyses. Data were summarized visually and narratively using standardized mean differences with 95% confidence intervals as the primary outcome of interest. A large proportion of meta-analyses investigated fibromyalgia or mixed chronic pain, and psychological interventions were most commonly evaluated. Acceptance and commitment therapy for general chronic pain, and fluoxetine and web-based psychotherapy for fibromyalgia showed the most robust effects and can be prioritized for implementation in clinical practice. Exercise for arthritis, pharmacotherapy for neuropathic pain, self-regulatory psychotherapy for axial pain, and music therapy for general chronic pain showed large, significant effects, but estimates were derived from low- or critically low-quality reviews. Conclusions: No single intervention type demonstrated substantial superiority across multiple pain populations. Other dimensions beyond efficacy, such as accessibility, safety, cost, patient preference, and efficacy for non-depressive outcomes should also be weighed when considering treatment options. Further effectiveness research is required for common pain types such as arthritis and axial pain, and common interventions such as opioids, anti-inflammatories and acupuncture.

12 October 2021 in Scientometrics
Verified
Journal Article
Open access
PDF file
ASAbhimanyu Sud
Abhimanyu Sud
DCDarren K. Cheng
Darren K. Cheng
RMRahim Moineddin
Rahim Moineddin
EZErin Zlahtic
Erin Zlahtic
RURoss Upshur
Ross Upshur
Bibliometric analyses of systematic reviews offer unique opportunities to explore the character of specific scientific fields. In this time series-based analysis, dynamics of multidisciplinary care for chronic pain and opioid prescribing are analyzed over a forty-four year time span. Three distinct periods are identified, each defined by distinct research areas, as well as priorities regarding the use of opioids and the appropriate management of chronic pain. These scientometrically defined periods align with timelines identified previously by narrative historical accounts. Through cross-correlation with a mortality time series, a significant two-year lag between opioid overdose mortality and citation dynamics is identified between 2004 and 2019. This analysis demonstrates a bidirectional relationship between the scientific literature and the North American opioid overdose crisis, suggesting that the scientific literature is both reflective and generative of an important health and social phenomenon. A scientometric phenomenon of memory lapse, namely an overt and prolonged failure to cite older relevant literature, is identified using a metric of mean time to citation. It is proposed that this metric can be used to analyze changes in emerging literature and thus predict the nature of clinical and policy responses to the opioid crisis, and thus potentially to other health and social phenomena.

7 April 2020 in Trials
Verified
Journal Article
Open access
PDF file
ASAbhimanyu Sud
Abhimanyu Sud
MNMichelle L. A. Nelson
Michelle L. A. Nelson
DCDarren K. Cheng
Darren K. Cheng
AAAlana Armas
Alana Armas
KFKirk Foat
Kirk Foat
RURoss Upshur
Ross Upshur
Background: Despite the high prevalence of comorbid chronic pain and depression, this comorbidity remains understudied. Meditation has demonstrated efficacy for both chronic pain and depression independently, yet there have been few studies examining its effectiveness when both conditions are present concurrently. Furthermore, while meditation is generally accepted as a safe and effective health intervention, little is known about how to implement meditation programs within or alongside the health care system. Methods: We will conduct a hybrid type 1 effectiveness–implementation evaluation. To measure effectiveness, we will conduct a randomized controlled trial comparing Sahaj Samadhi Meditation and the Health Enhancement Program in 160 people living with chronic pain, clinically significant depressive symptoms, and on long-term opioid therapy. Changes in depressive symptoms will be our primary outcome; pain severity, pain-related function, opioid use, and quality of life will be the secondary outcomes. The primary end point will be at 12 weeks with a secondary end point at 24 weeks to measure the sustainability of acute effects. Patients will be recruited from a community-based chronic pain clinic in a large urban center in Mississauga, Canada. The meditation program will be delivered in the clinical environment where patients normally receive their chronic pain care by certified meditation teachers who are not regulated health care providers. We will use a mixed-methods design using the multi-level framework to understand the implementation of this particular co-location model. Discussion: Results of this hybrid evaluation will add important knowledge about the effectiveness of meditation for managing depressive symptoms in people with chronic pain. The implementation evaluation will inform both effectiveness outcomes and future program development, scalability, and sustainability. Trial registration: ClinicalTrials.gov: NCT04039568. Registered on 31 July 2019.

1 June 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
DCDarren K Cheng
Darren K Cheng
RSRobert Simpson
Robert Simpson
RMRahim Moineddin
Rahim Moineddin
JKJoel Katz
Joel Katz
BMBenoit H Mulsant
Benoit H Mulsant
ASAbhimanyu Sud
Abhimanyu Sud
Background: Chronic pain (CP) often co-occurs with depression, but promising scalable interventions have been under-investigated. We assessed the effectiveness of the virtually-delivered Sahaj Samadhi Meditation (SSM) program in reducing depressive symptoms in people with CP and moderate depressive symptoms. Methods: We conducted a randomized controlled trial comparing SSM to the Health Enhancement Program (HEP), an active control. Participants were recruited from multiple sites in the Greater Toronto Area and virtually. Both 12-week programs were delivered virtually in groups by appropriately trained facilitators. Depressive symptoms were assessed using the Patient Health Questionnaire (PHQ-9) at baseline, 12 weeks, and 24 weeks. ClinicalTrials.gov registration number: NCT04039568. Results: Of 108 participants enrolled, 89 were randomized to SSM (n=43) or HEP (n=46). Between-group differences for the PHQ-9 were not significant. Within-group mean differences for SSM were significant and greater than the minimal clinically important difference at both 12 weeks and 24 weeks (− 3.97 (95% CI − 6.69 to − 1.24) and − 4.96 (− 8.36 to − 1.56), respectively), while within-group mean differences were not significant for HEP. Conclusion: This study suggests potential benefits of SSM for individuals with comorbid CP and depression. Future trials should include larger sample sizes in non-pandemic conditions to better evaluate the effectiveness of SSM. Further research should also explore pragmatic trial designs and the integration of mind-body interventions in clinical settings.

14 March 2020 in Research Square
Verified
Preprint
Open access
PDF file
ASAbhimanyu Sud
Abhimanyu Sud
MNMichelle L. A. Nelson
Michelle L. A. Nelson
DCDarren K. Cheng
Darren K. Cheng
AAAlana Armas
Alana Armas
KFKirk Foat
Kirk Foat
RURoss Upshur
Ross Upshur
Background: Despite the high prevalence of comorbid chronic pain and depression, this comorbidity remains understudied. Meditation has demonstrated efficacy for both chronic pain and depression independently, yet there have been few studies examining its effectiveness when both conditions are present concurrently. Furthermore, while meditation is generally accepted as a safe and effective health intervention, little is known about how to implement meditation programs within or alongside the healthcare system. Methods: We will conduct a hybrid type 1 effectiveness-implementation evaluation. To measure effectiveness, we will conduct a randomized controlled trial (RCT) comparing Sahaj Samadhi Meditation (SSM) versus the Health Enhancement Program (HEP) in 160 people living with chronic pain, clinically significant depressive symptoms, and on long-term opioid therapy. Changes in depressive symptoms will be our primary outcome; pain severity, pain related function, opioid use, and quality of life will be the secondary outcomes. The primary endpoint will be at 12 weeks with a secondary endpoint at 24 weeks to measure sustainability of acute effects. Patients will be recruited from a community-based chronic pain clinic in a large urban centre in Mississauga, Canada. The meditation program will be delivered in the clinical environment where patients normally receive their chronic pain care by certified meditation teachers who are not regulated healthcare providers. We will use a mixed-methods design using the multi-level framework to understand the implementation of this particular co-location model. Discussion: Results of this hybrid evaluation will add important knowledge about the effectiveness of meditation for managing depressive symptoms in people with chronic pain. The implementation evaluation will inform both effectiveness outcomes and future program development, scalability, and sustainability. Trial Registration: ClinicalTrials.gov: NCT04039568, registered July 31, 2019. https://clinicaltrials.gov/ct2/show/NCT04039568